Shares of Sarepta Therapeutics Inc have declined sharply, with continued concerns around reimbursement and competition. The shares could appreciate going ahead, driven by “the ongoing eteplirsen EU application review process and increasing visibility on a successful US launch,” Oppenheimer’s Hartaj Singh said in a report.Singh maintains an Outperform rating on the company, with a price target of $76.Raed more